UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2022

Transphorm, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-55832

(Commission File Number)

82-1858829

(I.R.S. Employer Identification No.)

75 Castilian Drive

Goleta, CA 93117
(Address of principal executive offices, including zip code)

(805) 456-1300

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

fy the filing obligation of the registrent under any of the following provisions

Seci	urities registered pursuant to Section 12(b) of the Act:
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Ciic	the depropriate tox below it the Form of Kinning is intended to simultaneously satisfy the timing obligation of the registrant under any of the following provisions.

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, par value \$0.0001 per share TGAN The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \square

Item 2.02 Results of Operations and Financial Condition.

On May 24, 2022, Transphorm, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The press release also announced that the Company would be hosting a webcast to discuss the financial results for the quarter on May 24, 2022. During the webcast, the Company will discuss the contents of a presentation prepared by the Company, a copy of which is furnished herewith as Exhibit 99.2 and is incorporated by reference herein.

The information furnished under this Item 2.02 and in the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in such filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated May 24, 2022
99.2	Investor Presentation, dated May 24, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
	2

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Transphorm, Inc.

Dated: May 24, 2022

By:

/s/ Cameron McAulay Cameron McAulay Chief Financial Officer



Exhibit 99.1

Transphorm Announces Record Fiscal 2022 Full Year Revenue of \$24.1 Million - an 89% Year-Over-Year Increase as Fiscal 2022 Fourth Quarter Revenue Increased 103%

- Company to Host a Webcast Today at 5:00 p.m. ET to Review the Quarterly Results and Provide a Business Update –

GOLETA, Calif.—May 24, 2022—Transphorm, Inc. (NASDAQ: TGAN)—an innovative design pioneer and global supplier of efficient, high-reliability, high-performance gallium nitride (GaN) power conversion products, announced today financial results for the Company's 2022 fiscal fourth quarter and the fiscal year ended March 31, 2022.

Fiscal Fourth Quarter and Recent Highlights

- · Achieved up listing of Transphorm's common stock to the NASDAQ under the ticker symbol TGAN.
- Full year FY22 revenue increased 89% year-over-year to a record \$24.1 million due to strong growth in product revenue based on prior targeted investments in designs for a broader market.
- FY22 product revenue increased sequentially for the ninth consecutive quarter to a record of over \$4 million, a 190 % sequential increase when compared to Q4 FY21.
- Secured largest SuperGaN® high-power Gen IV FET production order for the Company to date for over 500,000 units of 3kW class power supplies. The magnitude of this order clearly demonstrates Transphorm's continuing leadership in design innovation and manufacturing reliability of high-power GaN.
- Secured laptop adapter design-win from a Tier 1 Fortune 100 company, including an initial purchase order of 50,000 units of SuperGaN® Gen IV 240 mohm class FETs. These FETs provide higher efficiency for 65W fast-charging adapter applications versus competing e-mode GaN FETs that require a larger 150 mohm device for similar applications. As a result, these Transphorm SuperGaN® FETs allow our customers to do more with less.
- · Secured pre-production POs from ODMs for large Asia mobile phone (65W) and leading WW e-retailer (140W) projects
- Announced the first 99% efficient power switching demonstration from a 1200V GaN power transistor prototype, demonstrating Transphorm's cutting-edge innovation in high-power GaN.
- · Cash and equivalents as of March 31, 2022 were \$34.0 million.

Primit Parikh, Transphorm's President and Co-founder, commented, "We are excited to continue to deliver strong revenue growth, having achieved our 9th consecutive quarter of record product revenue. We also reaffirmed our leadership in high-power GaN by securing our largest order to date for over a half-million 3kW class GaN products.



Dr. Parikh continued, "The demand for our GaN solutions is strong, driven by our products' unique, easy to interface architecture, world leading GaN product portfolio with a broad range of power capabilities from 45W to 5kW, and leading performance with field reliability. With a strong backlog in place, our current focus is on managing supply chain constraints, expanding our manufacturing capacity, and continuing to grow our ecosystem of solution partners".

Cameron McAulay, CFO of Transphorm, stated "During the 2022 fiscal year we completed an uplisting to the NASDAQ, dramatically improving the Company's liquidity. Along with the additional capital we raised in fiscal Q3 of 2022, this provides expanded operational flexibility in support of our future anticipated growth."

Fiscal 2022 Fourth Quarter and Full Year Financial Results

Revenue for the 2022 fiscal fourth quarter was \$4.93 million, compared to \$4.6 million in the 2022 fiscal third quarter ended December 31, 2021 and \$2.4 million in the 2021 fiscal fourth quarter ended March 31, 2021. Revenue for the quarter reflected yet another record in product sales from ramping shipments of GaN devices for a broad range of power conversion applications, with an 10% sequential increase from the prior quarter. For the full fiscal year 2022, product sales increased 189% as compared to full fiscal year 2021.

Operating expenses on a GAAP basis were \$5.6 million in the 2022 fiscal fourth quarter, compared to \$5.4 million in the prior quarter and \$5.2 million in the 2021 fiscal fourth quarter operating expenses consisted of R&D expenses of \$1.6 million and SG&A expenses of \$4.0 million. On a non-GAAP basis, operating expenses in the 2022 fiscal fourth quarter were \$4.6 million, compared with non-GAAP operating expenses of \$4.4 million in the prior quarter and \$4.5 million in the 2021 fiscal fourth quarter.

GAAP net profit (loss) for the 2022 fiscal fourth quarter was (\$5.0) million, or (\$0.09) per share, compared to GAAP net loss of (\$4.2) million, or (\$0.08) per share, in the prior quarter, and a GAAP net loss of (\$6.6) million, or (\$0.16) per share, in the 2021 fiscal fourth quarter. On a non-GAAP basis, net loss for the 2022 fiscal fourth quarter was (\$4.0) million, or (\$0.08) per share, compared to non-GAAP net loss of (\$4.3) million, or (\$0.09) per share, in the prior quarter, and a non-GAAP net loss of (\$5.2) million, or (\$0.13) per share, in the 2021 fiscal fourth quarter.

Cash and equivalents as of March 31, 2022 were \$34 million, compared to \$9.5 million at March 31, 2021.

Wahaaa

Transphorm will host a webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the Company's 2022 fiscal fourth quarter and the fiscal year ended March 31, 2022 results and provide a business update. The webcast can be accessed at: https://event.on24.com/wcc/r/2947335/9EA3AFF729C086351F33CF46EFE76B59.

Investors and analysts may also join the conference call by dialing: 1 (888) 330-2446 or 1 (240) 789-2732 and providing the conference ID: 8060388.

A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company's website. Additionally, a telephone replay of the conference call will be available after the conclusion of the call and through May 31, 2022. The telephone replay can be accessed by dialing +1-800-770-2030 and entering the conference ID: 8060388.



About Transphorm

Transphorm, Înc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry's first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company's vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm's innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm_GaN.

Non-GAAP Financial Measures

This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm's ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm's results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income in joint venture.

A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning industry acceptance of GaN technology, the Company's ability to manage supply chain constraints, expand its manufacturing capacity, and grow its ecosystem of solution partners, and the Company's pipeline and future anticipated growth. Forward-looking statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to Transphorm's operations, such as additional financing requirements and access to capital; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company's filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.



Investor Contacts:
David Hanover or Jack Perkins
KCSA Strategic Communications
transphorm@kcsa.com

Company Contact: Cameron McAulay Chief Financial Officer 1-805-456-1300 ext. 140 cmcaulay@transphormusa.com



Transphorm, Inc. Condensed Consolidated Balance Sheets (in thousands)

		March 31, 2022 (unaudited)	December 31, 2021 (unaudited)	March 31, 2021 (audited)		
Assets						
Current assets:						
Cash and cash equivalents	\$	33,435	\$ 40,467	\$ 9,500		
Restricted cash		500	500	_		
Accounts receivable		2,632	2,489	1,618		
Inventory		6,330	5,956	2,223		
Prepaid expenses and other current assets		1,750	1,249	953		
Total current assets		44,647	50,661	14,294		
Property and equipment, net		1,796	1,897	1,360		
Goodwill		1,180	1,250	1,302		
Intangible assets, net		617	691	914		
Investment in joint venture		143	61	_		
Other assets		263	282	274		
Total assets	S	48,646	\$ 54,842	\$ 18,144		
Liabilities and stockholders' equity (deficit)						
Current liabilities:						
Accounts payable and accrued expenses	S	3,626	\$ 4,749	\$ 3,140		
Deferred revenue	3	308	267	505		
Development loan				10,000		
Revolving credit facility		180	368	10,150		
Unfunded commitment in joint venture		100		1,866		
Accrued payroll and benefits		1,171	1,239	1,410		
Total current liabilities		5,285	6,623	27,071		
Revolving credit facility		12,000	12,000	=		
Promissory note		12,000	12,000	16,128		
Total liabilities		17,285	18,623	43,199		
Commitments and contingencies		17,263	18,025	45,177		
Stockholders' equity (deficit):						
Common stock		5	5	4		
Additional paid-in capital		211,190	210,841	144,201		
Accumulated deficit		(178,638)	(173,639)	(168,403)		
Accumulated other comprehensive loss		(1,196)	(988)	(857)		
Total Stockholders' equity (deficit)		31,361	36,219	(25,055)		
Total liabilities and stockholders' equity (deficit)	s	48,646	\$ 54,842	\$ 18,144		
-1						



Transphorm, Inc. Condensed Consolidated Statements of Operations (in thousands except share and per share data)

Twelve Months Ended

March 31, 2021
(unaudited) Three Months Ended December 31, 2021 (unaudited) March 31, 2022 (unaudited) March 31, 2021 (audited) March 31, 2022 (unaudited) Revenue, net
Operating expenses:
Cost of goods sold
Research and development
Sales and marketing
General and administrative
Total operating expenses
Less frame operating expenses 7,015 5,898 2,319 3,789 1,632 1,047 3,935 1,609 976 2,852 1,788 1,780 663 2,733 12,530 6,655 3,535 9,969 25,201 (12,505) 2,917 11,226 9,372 (4,768) 33,946 (9,896) 6,964 (4,539) Loss from operations
Interest expense
Loss in joint venture
Changes in fair value of promissory note (4,458) 181 677 187 1,468 792 3,971 712 6.885 699 (314) (605) (3,819) 2,093 (1,940) (317) (1,503) Other income, net Loss before tax expense (4,164) (20,301) Tax expense (6,579) (0.16) 40,274,660 (20,301) (0.56) 36,555,353 (10,235) (0.22) 46,056,331 (4,999) (0.09) 53,343,862 (4,164) (0.08) 49,147,630 Net loss Net loss per share - basic and diluted Weighted average common shares outstanding - basic and diluted



Transphorm, Inc. Reconciliation of GAAP and Non-GAAP Financial Information (unaudited) (in thousands except share and per share data)

		Three Months Ended					Twelve Months Ended			
	Ma	rch 31, 2022	December 31, 2021		March 31, 2021		March 31, 2022		March 31, 2021	
GAAP net loss	\$	(4,999)	\$ (4,164)	S	(6,579)	S	(10,235)	\$	(20,301)	
Adjustments:										
Stock-based compensation		758	848		513		2,614		1,906	
Depreciation		147	142		123		546		500	
Amortization		74	74		74		296		296	
Changes in fair value of promissory note		_	_		699		(605)		2,139	
Other income (1)		_	(1,222)		_		(2,677)		_	
Total adjustments to GAAP net loss		979	(158)		1,409		174		4,841	
Non-GAAP net loss	\$	(4,020)	\$ (4,322)	S	(5,170)	\$	(10,061)	\$	(15,460)	
GAAP net loss per share - basic and diluted	\$	(0.09)	\$ (0.08)	S	(0.16)	\$	(0.22)	\$	(0.54)	
Adjustment		0.01	(0.01)		0.03		=		0.12	
Non-GAAP net loss per share - basic and diluted	\$	(0.08)	\$ (0.09)	S	(0.13)	\$	(0.22)	\$	(0.42)	
Weighted average common shares outstanding - basic and diluted		53,343,862	49,147,630		40,274,660		46,056,331		36,555,353	

(1) Other income consists of \$1.2 million gain upon the conversion of the Yaskawa Note for the three months ended December 31, 2021 and \$1.5 million gain upon termination of the joint venture agreement between Fujitsu Semiconductor Limited and Transphorm Aizu for the three months ended September 30, 2021.

	Three Months Ended					Twelve Months Ended			
	March 31, 2022		December 31, 2021		March 31, 2021		March 31, 2022		March 31, 2021
GAAP operating expenses	\$ 5,596	S	5,437	S	5,176	S	21,416	\$	18,186
Adjustments:									
Stock-based compensation	715		796		475		2,453		1,789
Depreciation	147		142		123		546		500
Amortization	74		74		74		296		296
Total adjustments to GAAP operating expenses	936		1,012		672		3,295		2,585
Non-GAAP operating expenses	\$ 4,660	\$	4,425	\$	4,504	\$	18,121	\$	15,601



Transphorm, Inc. Consolidated Statements of Cash Flows (unaudited) (in thousands)

Twelve Months Ended March 31, 2021 2022 Cash flows from operating activities: (10,235) \$ (20,301) Adjustments to reconcile net loss to net cash used in operating activities: Inventory write-off
Depreciation and amortization 273 842 796 62 Provision for doubtful accounts (8 000) (5,000) Licensing revenue from a related party Stock-based compensation 2,614 1,906 Interest cost 758 Gain on promissory note conversion Gain on sale of equipment (1.222)(40) Loss in joint venture 2 516 6.885 Changes in fair value of promissory note (605) 2,093 Changes in operating assets and liabilities: Accounts receivable (1,014) (267) (4,303) (297) (1,411) Prepaid expenses and other current assets Other assets 428 214 (132) Accounts payable and accrued expenses 236 Deferred revenue (197) 505 Accrued payroll and benefits (239) 334 Net cash used in operating activities (12,897) (19,590)Cash flows from investing activities: Purchases of property and equipment Investment in joint venture (742)(222)(6,768) (4,526) Net cash used in investing activities (5,268) (6,990) Cash flows from financing activities: Proceeds from sale of equipment 221 Proceeds from stock option exercise 16 Proceeds from issuance of common stock 49,773 14,596 Proceeds from exercise of warrants

Payment for taxes related to net share settlement of restricted stock units 272 (768) Net cash provided by financing activities 49,498 14,616 Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Net increase in cash, cash equivalents and restricted cash (205) 24,435 123 (**5,148**) Cash, cash equivalents and restricted cash at beginning of period 9,500 14,648 Cash, cash equivalents and restricted cash at end of period 33,935 9,500



Safe Harbor Statement

- This presentation is made solely for informational purposes, and no representation or warranty, express or implied, is made by Transphorm, Inc. ("Transphorm") or any of its representatives as to the information contained in these materials or disclosed during any related presentations or discussions. This presentation is intended solely for the purposes of familiarizing investors with Transphorm. This presentation is not an offer to sell nor does it seek an offer to buy any securities.
- This presentation contains forward-looking statements. All statements of the than statements of historical fact contained in this presentation, including statements regarding Transphorm's business strategy, plans and objectives for future operations, expectations regarding its total addressable market, products, and competitive position, are forward-looking statements. The words "may," "will," "estimate," "expect," "plan," "believe," "potential," "predict," "target," "should," "would," "could," "continue," "believe," "project," "intend" or similar terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
- Transphorm may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These statements are based upon management's current expectations, assumptions and estimates, and are not guarantees of future results or the timing thereof. Actual results may differ materially from those contemplated in these statements due to a variety of risks and uncertainties, including risks and uncertainties related to Transphorm's business and financial performance and cash flows and its ability to reduce operating losses and achieve profitability, attract and retain customers, continue commercial production, continue to access funding sources to finance operations, continue having access to third party manufacturers, develop new products, enhance existing products, compete effectively, manage growth and costs, and execute on its business strategy. The forward-looking statements contained in this presentation are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended December 31, 2021, filed with the Securities and Exchange Commission on February 10, 2022
- The information contained herein is provided only as of the date on which this
 presentation is made and is subject to change. Transphorm is not under any
 obligation, except as may be required by law, to update or otherwise revise the
 information after the date of this presentation. Transphorm has not independently
 verified the statistical and other industry data generated by independent parties
 and contained in this presentation and accordingly cannot guarantee their
 accuracy or completeness.

transphorm
NASDAQ: TGAN

Key Investment Highlights

GaN Power Semiconductor Pioneer and Leader

Disruptive Technology

GaN Enables Next Generation Power Conversion Solutions – 99% Efficiency¹, 50% More Compact/Lightweight, Lower System Cost

Large Market Opportunity

Transphorm's GaN Solutions will Enable the Future of Electric Vehicles and Fast-charging for 5G – Contributing to GaN TAM growing to \$68² in 2026

REVOLUTION

completed, Integrated Manufacturing, \$24.1M FY-22 Revenues, Target >50% LT CAGR Best-In-Class Differentiated GaN

Manufacturing Base

Ramping Commercially with Strong

Technology and Product Development

IP Portfolio Appraised in Excess of \$200M³ Leader in Quality + Reliability, > 40 Billion Field hours, Silicon-like Reliability⁴

Technology + Industry's Strongest IP Position

Team Led by World-Renowned GaN Experts

Proven Leadership, 18 PhDs and Over 300 Years of GaN Expertise

Validation From Blue Chip Partners and Customers

Including KKR, Marelli, Yaskawa, SAS, Nexperia, Microchip, Diodes and the U.S. DoD(Navy), DOE


transphorm NASDAQ: TGAN

Measured TGAN >99% efficient power stages, commercial implementations
 See slide 10 on GaN TAM Analysis

3 2021 Analysis done for GaN portfolio using Intracom Group Intellectual Property Solutions' patent valuation models based on 27 independent criteria, value consists of Transphorm's owned or exclusively licensed patents (non-exclusive patents not included) 4 Based on filed performance, low power and high power das, fill ("Fallure I Imale > 0.3.) Billion hours

Target Operating Model

Building a High-Growth, Product Driven Cash Generating Business



Operating Guidelines:

- Rapid top-line growth
 and GaN adoption across multiple
 end markets
- OpEx for continued development of best-in-class products and IP portfolio
- CAPEX investment for increased scale

Target Model:

5-year CAGR range: 50%+

Gross Margin: 40%+

Operating Margin: 20%+

Free Cash Flow: 10%+

transphorm NASDAQ: TGAN

.

Targeting \$3 Billion Power Market Opportunity in 2023

Upside to TAM from Electric Vehicle Powertrain starting in 2025

End Market Applications and GaN Benefits

Near Term

Power Adapters | Compute

Data Center | Comm Infrastructure | Crypto-Mining

Broad Industrial

Automotive EV and Charging | + EV Powertrain from 2025

Long Term

- Fast charging
- Lower thermals/ smaller form factor
- Lower system cost
- Ability to double available power in standardized server and 5G telecom form factors
- Enable Titanium-class efficiency EU requirement
- Reduces size/weight of systems
- More efficient charging for battery and/or batterypowered equipment and vehicles
- Reduces size/weight of onboard chargers, power converters and power inverters
- Resulting in longer distance per charge










End customers already in Production with TPH GaN-45W to 4 kW

transphorm NASDAQ: TGAN



1 Market access based on current, future device offerings with operations to support shipments. Does not include the adoption of GaN technology nor Transphorm's yearly adoption rat 2 Shows the Devador, potential GaN market size, does not include any adoption rate 3 Includes modules for EV inverter and EV fast charging starting in 2024 and beyond 45e eappendis for references transphorm NASDAQ: TGAN

Transphorm Advantage: Enabling Customers by Taking GaN Benefits to the Next Level

Faster, Smaller, More Efficient and Robust Solutions

Intrinsic Benefits of GaN									
Performance	Field-proven best-in-class efficiencyDemonstrated and in volume over wide power levels								
Quality & Reliability	 JEDEC + AEC-Q101, best-in-class robustness < 0.3 FIT > 40B hours 								
Volume Production Capability	In-house GaN supply, vertically integrated value chainCapacity to support higher unit volumes								
Comprehensive Product Portfolio	 Products span low-to-high power, 45W to +10kW Only company with 900V GaN, 1200V and short circuit in R&D 								
Ease of Drivability and Design-in	 Compatibility with standard Silicon packages w/ superior thermal heatsink capability Growing number of reference designs and IC partners 								
Patent & IP Coverage	Industry's strongest GaN IP position with >1K patents • From material and process to design and application								

transphorm NASDAQ: TGAN



Asset-Light, Vertically Integrated Manufacturing Driving Innovation

Transphorm



1. GaN FET design

(Safe Normally Off, Robust, High Performance, Easy to interface)

Transphorm



2. Core Epi wafer starting material and manufacturing (Multiple

MOCVD Reactors, 6", 8" capable)

Transphorm (JV)

3. Wafer fab - AFSW (GaN with Si-like yields¹)

Transphorm and Partners



4. Packaging

Sub-con partners

(Use Multiple OSATs, with TGAN IP)




(Easy to Design for Partners)

 P. Parikh et. al., GaN Power Commercialization with Highest Quality-Highest Reliability 650V HEMTs- Requirements, Successe and Challenges, 2018 IEEE International Electron Devices Meeting (IEDM), Dec 2018 transphorm NASDAQ: TGAN

Comprehensive GaN Product Portfolio: 45 W to +10 kW

TGAN Core Platform Spanning the Power Spectrum: Wide breadth of 650V, 900V JEDEC/AEC-Q101 Qualified Products, 1200V and short circuit in R&D



UPS transphorm
NASDAQ: TGAN

TPH GaN vs. e-mode GaN: Why We Win!

Key Factors	Silicon MOSFET	e-mode GaN	Transphorm GaN FET
Ease of use (std. drivers, agnostic to controllers)	•	•	•
Size (form factor) and Speed (frequency)		•	
Performance (efficiency) ¹			
Added BoM components (cost)2	•	•	•
Reliability and Robustness ³		•	•

transphorm NASDAQ: TGAN

Strong

Medium

Weak

1.2Based on multiple public and internal reference designs, https://www.transphormusa.com/en/reference-design/tsadp-sil-usbc-65w-rd/
2Impact of OFF-state Gate Blas on Dynamic R,on of p-GaN Gate HEMT (33°4 ISPSD, 2021)

TGAN FET: Higher Range, Reliability & Performance Spanning Low to High Power

Why Transphorm Wins:

- Transphorm adopted in many more markets
- "e-mode" input interface is weaker hard to operate in widely used TO Packages for higher power
- Superior Dynamic performance from TGAN FET Strong performance, from smaller GaN die
- Proven reliability & manufacturing for scaled device
 10 kW capable single GaN device in production

In Production ¹											
Markets	GaN IC	GaN FET	Power Range TGAN Wins								
Adapters	~	~	30-250W								
Datacenters	×	~	800-3200W								
Gaming (Desktop)	×	~	1600W								
Crypto mining	×	~	1600-3600W								
Industrial (≥ 500 W)	×	~	500-3000W								
Aerospace	×	~	420-1200W								

1. Based on our best knowledge of released products and in volume production with customers' systems

transphorm NASDAQ: TGAN

Myths/Mis-information

Myths Clarified: "IC" or Discrete Integrated or Other – Performance/Ease of Use/Reliability/Cost is what matters

Normally off: "e-mode/ d-mode"

Fact:

Customer/Application demands Normally off Transistor.

TGAN FETs are Normally Off - just like MOSFETS

TPH GaN FET vs GaN IC Performance

Fact:

GaN FET solution proven higher performance.

For example, in comparable adapter solutions.

Drivers/ Integration


Fact:

Many modern controllers have drivers integrated (free), TGAN FETs – No extra driver or interfacing need, and where drivers needed, it is a Siliconlike interface.

> transphorm NASDAQ: TGAN

Transphorm GaN FET Outperforms the Competition

SuperGaN® offers reduced power loss (25-38%) over SiC FETs



Recent 3rd party independent validation: 15-20% loss reduction (0.5-1% point efficiency improvement) at 5 kW in a resonant converter ¹

Device Power Loss Comparison (9.2 kW) (Limited due to SiC FET junction temperature)

1. PCIM 2022, Technical Paper, Alejandro Llop et. al., "A Comparison among Wide Bandgap Devices using a CLLLC Bidirectional Resonant Converter"

transphorm
NASDAQ: TGAN

Customers Select Transphorm GaN

Efficient, Reliable, Highest Performance, East of Drivability and Designability



"The Corsair
AX1600i is the best
PSU that money can
buy today, period."
tom's HARDWARE

"Based largely on the power semiconductors' proven quality and reliability as well as the team's reputation for successful collaboration,"





5' 9

"Ease of drivability and designability—does not require custom drivers. Proven reliability — JEDEC and AEC-Q101"

"Transphorm's GaN within a totem-pole PFC configuration proved the most reliable, highest performing solution possible today,"



transphorm NASDAQ: TGAN

Leadership in High-Power GaN – Secured new PO >500,000 units

Efficient, Reliable, High Performance, Patented GaN Architecture

<u>Block Chain Computing – Power Hungry Systems</u> requiring Titanium efficiency







- Consumes ~120 TWh, equivalent to small country
- TGAN solutions can enable up to 1% higher efficiency
 - 230 V_{AC} (> 125 lbs of CO₂ emissions / TGAN Device¹)
 Greater than 50,000 metric tons in 2022

<u>Data Center Server Power – We have enabled</u> <u>Titanium performance for > 4 years</u>




- 5 MW Data center, \$103K saved / year, 397 tons reduced carbon footprint²
- Regulations like EU Ecodesign³ in 2023 expected to accelerate GaN adoption
 - · Increased order from existing customer

Notes:

- Based on company estimates done for a SMW data center.
 Based on existing rectifiers with 92% efficiency | Source: EPA estimated one kWh produces 1.52 pounds of carbon dioxide (expenses).
- 3) European Union's Ecodesign Directive (Directive 2009/125/EC).

transphorm
NASDAQ: TGAN

GaN Enables Future of Next-Gen Electric Vehicles



transphorm
NASDAQ: TGAN

Accelerating Opportunity for GaN Enabled Power in EV

GaN Opportunities in EV



Addressable GaN \$ Content/EV²



- Well-positioned for automotive opportunity with leading products, strategic partners
- EV Adoption increasing to 32 million (44 million hyper adoption) vehicles by 2030¹

Transphorm GaN AEC-Q101 (Automotive) Qualified NOW

transphorm NASDAQ: TGAN

1 IHS and Goldman Sachs Global Investment Research
2 Transphorm company internal estimates, 2022 includes ORC/DCRC, 2025 includes invester (100kw

Strong QoQ of Product Revenue Growth

- Maintaining leadership in higher power markets (1-5kW segment): Captured recent >500,000 units order (1 large device ~ 8 smaller Adapter/charger devices)
- Gain share in Adapter/chargers with superior performance, strong solutions partners



Key Business Focus – Scaling Product Revenue

Focus on Product Revenue Growth, Supply Chain and Expanding Capacity

War francisco	Activities	and the same of th
Key focus area	Achieved	Comments
1. Revenue/Products	✓ \$4M Products (Total \$4.93M)	9th sequentially higher Qtr.Robust demand, strong backlog
2. Adapters/Chargers: Design- ins, Production, Solutions (45W – 250W)	 ✓ Design-Ins: >55 (>5 added) ✓ In Production: >20 ✓ Solutions/Ref designs: >12 	 Laptop win, 50K units PO Easy to use, no added driver, Small die vs. e-mode Pilot wins at major Tier 1s
3. High power: Design-Ins, Production, Ref. Designs (300W-4kW)	 ✓ Design-Ins: >35 (> 5 added) ✓ In Production: >15 ✓ Eval kits/Ref designs: >8 (1-4kW) 	 >500K units PO for 3kW+ >50% of revenue High Power Next: Expand & Dominate
4. Product SKUs and Qualification	✓ Total: 17 (AEC qualified: 3) ✓ 1200V R&D Demo (@ Major IEEE Conf.)	 Broadest offering (650/900V), Compact surface-mount & thermally robust TOs Next: Gen5 AEC qualification
5. Capacity Proof Points	✓ Lower power (PQFN) – multiple sources in place ✓ Higher power (TO247) –1st 5 months of CY'22 > all of CY'21	Focus - Supply chain management Epi , Fab Wafer capacity expansion ongoing

transphorm NASDAQ: TGAN

Key Business Update - Strategic Partnerships

Manufacturing, Capacity Increase Partnerships

- Global Wafers (Partner) Epiwafer expansion on track (completion in mid-CY 2023)
- AFSW Fab (Transphorm's JV) Managing with GaNovation (Financial-Strategic partner) and planning for increases in 2H'CY 22 and 2023 to keep up with increasing demand

1100

Industrial and Automotive

- Yaskawa (Industrial) Program aligned for cost effective innovative solutions for robotic applications
 - Development funding to be completed
- Nexperia (Automotive focus) Continued epi and fab wafer supply, next milestone Gen5 AEC qual,
 Marelli (Automotive) Ongoing development phase, with Gen IV/Gen V: Charger/Converter, Inverter
 - Other: Continuing design-ins with other Japan EV, for CY 2023-2024 dc-dc and obc opportunities

Government Revenue and Epi Business

- Navy and Govt. Programs On track, \$0.9m in FQ4'22. Epi for RF (Navy, DARPA), 1200V R&D (ARPA-E)
- Additional Epi customers (rf) Ongoing, primary focus on internal power products ramp



transphorm NASDAQ: TGAN

Key Financial Highlights

Record Product Revenue, Improving EPS, TGAN now on NASDAQ

	Q4 FY2022	FY2022	Commentary
Revenue	\$4.9m (> 80% Product)	\$24.1m (> 50% product)	9 successive quarters of revenue growth Total Revenue increased 7% from Q3, 89% from FY21 Product revenue increased 10% from Q3, 190% from FY22
Gross Margin	23%	48%	 FY2022 blended margin of 48% (FY21 – 45%) Gross margin progressing toward long term model
OPEX (non-GAAP)	\$4.6m	\$18.1m	5% increase in quarter, 16% increase from FY21Increases largely driven by staffing
EPS (non-GAAP)	(\$0.08)	(\$0.22)	 Solid improvement in EPS Q3 FY22 EPS (\$0.09) and FY21 EPS (\$0.42)
Stockholders Equity	\$3	2m	Stockholder's equity improved \$56m from FY21 Strong equity raises, Yaskawa loan conversion and execution on Development loan
Operational Notables	1		Record quarterly product bookingsStrong Backlog in place to support growth

transphorm NASDAQ: TGAN

Positioned to Grow Across Multiple Segments







5G Market Adoption





Electric Vehicle (EV) Market Adoption

Adoption / Growth

Execution and Expansion

Achieve Target Model

CY 2021-2022

CY 2023

CY 2024+

- Multiple revenue streams in place
- Growing production across multiple segments
- Shipped > 1M units in December 2021
- Continued investment in growth across all aspects of the company Investing in capacity increases
- **Broad market inflection point**
- Ramping revenue across consumer, data centers and crypto segments
- Continue to scale capacity aggressively
- Initial wins in automotive segment Continued government contracts
- Continued momentum and broad market expansion
- Automotive adoption growth
- Leader in High Power, EV, Consumer segments
- Positive cash flow generation
- Execute to target model

transphorm NASDAQ: TGAN

Key Investment Highlights

GaN Power Semiconductor Pioneer and Leader

Disruptive Technology

GaN Enables Next Generation Power Conversion Solutions – 99% Efficiency¹, 50% More Compact/Lightweight, Lower System Cost

Large Market Opportunity

Transphorm's GaN Solutions will Enable the Future of Electric Vehicles and Fast-charging for 5G -Contributing to GaN TAM growing to \$6B² in 2026

Validation From Blue Chip Partners and Customers

Including KKR, Marelli, Yaskawa, SAS, Nexperia, Microchip, Diodes and the U.S. DoD(Navy), DOE

Ramping Commercially with Strong Manufacturing Base

Technology and Product Development completed, Integrated Manufacturing, \$24.1M FY-22 Revenues, Target >50% LT CAGR

Best-In-Class Differentiated GaN Technology + Industry's Strongest IP Position

IP Portfolio Appraised in Excess of \$200M³ Leader in Quality + Reliability, > 40 Billion Field hours, Silicon-like Reliability⁴

Team Led by World-Renowned GaN Experts

Proven Leadership, 18 PhDs and Over 300 Years of **GaN** Expertise

1 Measured TGAN >99% efficient power stages, commercial implementations 2 See slide 10 on GaN TAM Analysis

3 2021 Analysis done for GaN portfolio using Intracom Group Intellectual Property Solutions' patent valuation models based on 27 independent criteria, value consists of Transphorm's owned or exclusively licensed patents (non-exclusive patents not included) 4 Based on filed performance, low power and high power das, fill ("Fallure I Imale > 0.3.) Billion hours

transphorm NASDAQ: TGAN

Appendices

transphorm NASDAQ: TGAN

Consolidated Balance Sheets

Transphorm, Inc. Condensed Consolidated Balance Sheets (in thousands)

		ch 31, 2022 naudited)		nber 31, 2021 naudited)	March 31, 2021 (audited)		
Assets					_		
Current assets:							
Cash and cash equivalents	\$	33,435	\$	40,467	\$	9,500	
Restricted cash		500		500		_	
Accounts receivable		2,632		2,489		1,618	
Inventory		6,330		5,956		2,22	
Prepaid expenses and other current assets		1,750		1,249		953	
Total current assets		44,647		50,661		14,294	
Property and equipment, net		1,796		1,897		1,360	
Goodwill		1,180		1,250		1,300	
Intangible assets, net		617		691		91	
Investment in joint venture		143		61		_	
Other assets		263		282		27-	
Total assets	\$	48,646	\$	54,842	\$	18,14	
Liabilities and stockholders' equity (deficit)							
Current liabilities:							
Accounts payable and accrued expenses	\$	3,626	\$	4,749	\$	3,14	
Deferred revenue		308		267		50	
Development loan		_		_		10,00	
Revolving credit facility		180		368		10,15	
Unfunded commitment in joint venture		_		_		1,86	
Accrued payroll and benefits		1,171		1,239		1,41	
Total current liabilities		5,285		6,623		27,07	
Revolving credit facility		12,000		12,000		-	
Promissory note		_		_		16,12	
Total liabilities		17,285		18,623		43,19	
Commitments and contingencies							
Stockholders' equity (deficit):							
Common stock		5		5			
Additional paid-in capital		211,190		210,841		144,20	
Accumulated deficit		(178,638)		(173.639)		(168,40)	
Accumulated other comprehensive loss	100	(1,196)	0	(988)	10	(85)	
Total Stockholders' equity (deficit)		31,361	_	36,219		(25,055	
Total liabilities and stockholders' equity (deficit)	5	48,646	\$	54,842	\$	18,14	

Subject to completion of audit procedures

transphorm NASDAQ: TGAN

Condensed Consolidated Statements of Operations

Transphorm, Inc. Condensed Consolidated Statements of Operations (in thousands except share and per share data)

	Three Months Ended						Twelve Mouths Ended			
	th 31, 2022 (sudited)		2021 unsudited)	M	arch 31, 2021 (nudited)		arch 31, 2022 unaudited)		rch 31, 2021 inaudited)	
Revenue, net	\$ 4,927	2	4,604	5	2,425	5	24,050	5	12,696	
Operating expenses:										
Cost of goods sold	3,789		3,935		1,788		12,530		7,015	
Research and development	1,632		1,609		1,780		6,655		5,898	
Sales and marketing	1,047		976		663		3,535		2,319	
General and administrative	2,917		2,852		2,733		11,226		9,969	
Total operating expenses	9,385		9,372		6,964		33,946		25,201	
Loss from operations	(4,458)		(4,768)		(4,539)		(9,896)		(12,505)	
Interest expense	181		187		187		792		758	
Loss in joint venture	677		712		1,468		3,971		6,885	
Changes in fair value of promissory note	_		_		699		(605)		2,093	
Other income, net	(317)		(1,503)		(314)		(3,819)		(1,940)	
Loss before tax expense	(4,999)		(4,164)		(6,579)		(10,235)		(20,301)	
Tax expense	_		_		-		_		-	
Net loss	\$ (4,999)	\$	(4,164)	\$	(6,579)	\$	(10,235)	\$	(20,301)	
Net loss per share - basic and diluted	\$ (0.09)	\$	(0.08)	\$	(0.16)	\$	(0.22)	\$	(0.56)	
Weighted average common shares outstanding - basic and diluted	53,343,862		49,147,630		40,274,660		46,056,331		36,555,353	

Subject to completion of audit procedures

transphorm NASDAQ: TGAN

GAAP to NON-GAAP Reconciliation

Transphorm, Inc. Reconciliation of GAAP and Non-GAAP Financial Information (unaudited) (in thousands except share and per share data)

	Three Months Ended					Twelve Months Ended				
	7	farch 31, 2022		December 31, 2021		March 31, 2021	7	farch 31, 2022	λ	farch 31, 2021
GAAP net loss	\$	(4,999)	\$	(4,164)	\$	(6,579)	\$	(10,235)	\$	(20,301
Adjustments:										
Stock-based compensation		758		848		513		2,614		1,906
Depreciation		147		142		123		546		500
Amortization		74		74		74		296		296
Changes in fair value of promissory note		_		_		699		(605)		2,139
Other income (1)		-		(1,222)				(2,677)		_
Total adjustments to GAAP net loss		979	_	(158)	Ξ	1,409		174	_	4,841
Non-GAAP net loss	\$	(4,020)	S	(4,322)	\$	(5,170)	\$	(10,061)	\$	(15,460)
GAAP net loss per share - basic and diluted	\$	(0.09)	\$	(0.08)	\$	(0.16)	\$	(0.22)	\$	(0.54
Adjustment		0.01	_	(0.01)	_	0.03	_	_		0.12
Non-GAAP net loss per share - basic and diluted	5	(0.08)	s	(0.09)	s	(0.13)	s	(0.22)	s	(0.42
Weighted average common shares outstanding - basic and diluted	- 4	3,343,862	Ξ	49,147,630	Ξ	40,274,660		46,056,331	1	36,555,353

(1) Other income consists of \$1.2 million gain upon the convenion of the Yaskawa Note for the three months ended December 31, 2021 and \$1.5 million gain upon termination of the joint ventures agreement between Fujirus Semiconducter Limited and Transphorm Airus for the three months ended Superador 90, 2021.

	Three Months Ended						Twelve Months Ended			
	М	arch 31, 2022		cember 1, 2021	M	arch 31, 2021	M	arch 31, 2022	M	arch 31, 2021
GAAP operating expenses	\$	5,596	\$	5,437	\$	5,176	\$	21,416	5	18,186
Adjustments:										
Stock-based compensation		715		796		475		2,453		1,789
Depreciation		147		142		123		546		500
Amortization		74		74		74		296		296
Total adjustments to GAAP operating expenses		936		1,012		672		3,295		2,585
Non-GAAP operating expenses	\$	4,660	S	4,425	5	4,504	\$	18,121	5	15,601

Subject to completion of audit procedures

transphorm NASDAQ: TGAN

